Cargando…
P18-03. Dendritic cell-based immune therapy against HIV-1
Autores principales: | Gruters, RA, de Keersmaecker, B, de Goede, AL, Allard, SD, Koetsveld, J, Corthals, J, Schutten, M, Heirman, C, Ende, ME van der, Lacor, P, Osterhaus, AD, Thielemans, K, van Baalen, CA, Aerts, JL |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767818/ http://dx.doi.org/10.1186/1742-4690-6-S3-P312 |
Ejemplares similares
-
Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
por: Wilgenhof, Sofie, et al.
Publicado: (2015) -
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014) -
Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
por: Benteyn, Daphné, et al.
Publicado: (2013) -
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020) -
Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production
por: Broos, Katrijn, et al.
Publicado: (2019)